Skip to content
‹ Back to IndustriesHealthcare

Ultrasound Technology to Diagnose and Treat Cardiovascular Disease

Ultrasound analysis leads the charge in advancements in diagnosing and treating cardiovascular disease. Intel’s Yehudit Levi and DiA Imaging Analysis’ Hila Goldman-Aslan joined Michelle Dawn Mooney for insights on the AI and technology advancements in ultrasound that provide better diagnosis and treatment of cardiovascular disease. Hila Goldman-Aslan says that early detection is the go-to strategy…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Ultrasound analysis leads the charge in advancements in diagnosing and treating cardiovascular disease. Intel’s Yehudit Levi and DiA Imaging Analysis’ Hila Goldman-Aslan joined Michelle Dawn Mooney for insights on the AI and technology advancements in ultrasound that provide better diagnosis and treatment of cardiovascular disease.

Hila Goldman-Aslan says that early detection is the go-to strategy to prevent a significant cardiac incident or death. “And ultrasound is the leading modality to identify those abnormalities in the heart, and it’s been increasingly used in all kinds of settings. You can see an ultrasound and cardiac ultrasound being used at the point of care in the emergency rooms and the ICU.”

A 2020 article from the American College of cardiology notes a rise in cardiovascular disease. With one-third of global deaths in 2019 attributed to cardiovascular disease, it is critical to find preventative solutions to reduce these alarming numbers. And this situation is where AI can play an essential role. “Artificial intelligence is all about data,” says Yehudit Levi. “The health segment is unique in the sense that a lot of medical records have been collected through the years. Artificial intelligence software enables processing these masses of data.” The insights gleaned from all this data and knowledge, once made accessible to the medical staff, help highlight abnormalities that might otherwise prove difficult to detect.

DiA Imaging Analysis powered through Intel technology strives to allow for more efficient cardiovascular results and better treatment. “We see physicians looking for more automated procedures and processes to help them make better decisions based on more objective information,” Goldman-Aslan says. Until recently, the review of ultrasound images relied solely on the operator, which creates a layer of subjectivity. With AI analysis, the process becomes more objective and provides better information for the cardiovascular team to make decisions. The increase in cardiac procedures and a shortage of staff analysts available make DiA Imaging ultrasound analysis solutions integral.

“Improving the diagnostic time is super important,” Levi stresses. “It allows more patients to be diagnosed.” Together, DiA and Intel make these ultrasound capabilities scalable for healthcare.

Learn more about Health and Life Sciences by connecting with Yehudit Levi and Hila Goldman-Aslan on LinkedIn or visit: 

 Subscribe to this channel on Apple Podcasts, Spotify, and Google Podcasts to hear more from the Intel Internet of Things Group.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Pharma rates its follow-through on diagnostic data 5.2 out of 10 in Diaceutics survey

Pharma rates its follow-through on diagnostic data 5.2 out of 10 in Diaceutics survey

In a Diaceutics survey of 125 US pharma leaders, respondents rated the significance of converting diagnosis into treatment to future commercial success at an average of 7.5 out of 10. They rated their organizations' effectiveness at turning diagnostic insights into coordinated action at just 5.2 out of 10. Separate Diaceutics lung cancer research found the largest gap now occurs at the point of treatment decision.

  • 01Pharma leaders rated their confidence in identifying eligible patients at 6.6 out of 10, their visibility across the patient journey at 5.4 and their effectiveness at turning diagnostic insights into coordinated action at 5.2. The low last score could point to the treatment decision, where Diaceutics' lung cancer research found the largest gap now occurs.
  • 02In US advanced non-small cell lung cancer, Diaceutics found overall patient loss virtually unchanged at 65.1% in 2023 versus 64.4% in 2019, while patient loss at the point of treatment decision rose from 29.2% to 43.3%. For operators, a flat headline rate could hide one step getting worse.
  • 03Senior leaders from several top 20 pharma companies argue diagnostic planning belongs early in development and commercialization, rather than as a testing and adoption fix after launch.

Nov 22, 2026

Frequent use of clinical AI tools rose to 34% in Elsevier's 2026 clinician survey

Elsevier's Clinician of the Future 2026 survey found 49% of clinicians use AI at work. Purpose-built clinical AI is gaining fast. Its frequent use rose from 22% in 2025 to 34% this year, yet 41% of nurses say their views are rarely or never sufficiently considered in important organizational decisions.

  • 01A sharper vendor question: which evidence base grounds the tool's answers, and can a clinician see that source at the moment of use? Transparency and authoritative data top clinicians' own list of what builds trust.

Nov 22, 2026

Zoom's stake in Medaica aims to bring the physical exam into video visits

Zoom Ventures made an undisclosed strategic investment in Medaica, whose FDA-cleared M1 telehealth stethoscope supports real-time remote heart and lung auscultation. Zoom already integrates with EHRs including Epic, Oracle Cerner Millennium and Athenahealth, but an investment is not an integration and no combined product has been announced. Cardiology follow-ups and care facilities are highlighted as likely early use cases.

  • 01Video gave telehealth the patient's face; an FDA-cleared remote stethoscope adds the heartbeat, and Zoom now has a financial stake in that second layer.
  • 02Today's cleared capability is real-time heart and lung auscultation; the wider mix of third-party devices, AI analysis and decision support is still in development.
  • 03For health systems with elderly or rural cardiology panels, the sharper vendor question is how exam findings reach the EHR record of the visit.

Nov 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512